As of 2025-07-13, the EV/EBITDA ratio of Concord Drugs Ltd (538965.BO) is 13.85. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 538965.BO's latest enterprise value is 574.81 mil INR. 538965.BO's TTM EBITDA according to its financial statements is 41.49 mil INR. Dividing these 2 quantities gives us the above 538965.BO EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 9.4x - 11.5x | 10.3x |
| Forward P/E multiples | 7.0x - 7.7x | 7.2x |
| Fair Price | 22.95 - 45.36 | 31.01 |
| Upside | -62.5% - -25.8% | -49.3% |
| Date | EV/EBITDA |
| 2025-07-07 | 12.60 |
| 2025-07-04 | 12.21 |
| 2025-07-03 | 12.59 |
| 2025-07-02 | 12.34 |
| 2025-07-01 | 12.08 |
| 2025-06-30 | 10.85 |
| 2025-06-27 | 10.04 |
| 2025-06-26 | 9.40 |
| 2025-06-25 | 9.28 |
| 2025-06-24 | 9.43 |
| 2025-06-23 | 9.13 |
| 2025-06-20 | 9.20 |
| 2025-06-19 | 9.25 |
| 2025-06-18 | 9.23 |
| 2025-06-17 | 9.13 |
| 2025-06-16 | 9.11 |
| 2025-06-13 | 9.24 |
| 2025-06-12 | 9.24 |
| 2025-06-11 | 9.28 |
| 2025-06-10 | 9.51 |
| 2025-06-09 | 9.43 |
| 2025-06-06 | 9.43 |
| 2025-06-05 | 9.57 |
| 2025-06-04 | 9.33 |
| 2025-06-03 | 9.42 |
| 2025-06-02 | 9.33 |
| 2025-05-30 | 9.40 |
| 2025-05-29 | 9.43 |
| 2025-05-28 | 9.31 |
| 2025-05-27 | 9.37 |
| 2025-05-26 | 9.41 |
| 2025-05-23 | 9.51 |
| 2025-05-22 | 9.36 |
| 2025-05-21 | 9.41 |
| 2025-05-20 | 9.48 |
| 2025-05-19 | 9.47 |
| 2025-05-16 | 9.51 |
| 2025-05-15 | 9.43 |
| 2025-05-14 | 9.23 |
| 2025-05-13 | 9.19 |
| 2025-05-12 | 9.40 |
| 2025-05-09 | 9.23 |
| 2025-05-07 | 9.15 |
| 2025-05-06 | 9.27 |
| 2025-05-05 | 9.28 |
| 2025-05-02 | 9.12 |
| 2025-04-30 | 9.12 |
| 2025-04-29 | 9.09 |
| 2025-04-28 | 9.21 |
| 2025-04-25 | 9.16 |